Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.20.1
Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Organization And Summary Of Significant Accounting Policies [Line Items]      
Reclassification from deferred revenue, current to deferred revenue, current, related party $ 8,773   $ 8,780
Reclassification from deferred revenue, non-current to deferred revenue, non-current, related party     $ 400
Reclassification from deferred revenue to deferred revenue, related party (907) $ 7,529  
Cash, cash equivalents, and marketable securities $ 108,000    
Revenue | Credit Risk | Vertex Pharmaceuticals Inc      
Organization And Summary Of Significant Accounting Policies [Line Items]      
Percentage of total revenues 35.00% 0.00%  
Revenue | Credit Risk | Takeda Pharmaceuticals Inc      
Organization And Summary Of Significant Accounting Policies [Line Items]      
Percentage of total revenues 8.00% 92.00%  
Other Assets      
Organization And Summary Of Significant Accounting Policies [Line Items]      
Restricted cash $ 3,000